Cargando…
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
BACKGROUND: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo. This is a first-in-human trial of this antibody. MATERIALS AND METHODS: YYB101 was administered intravenously to refractory cancer patients once every 4 wee...
Autores principales: | Kim, Seung Tae, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Whan, Park, Neunggyu, Lee, Hukeun, Hong, Sung Hee, Lee, Song-Jae, Song, Seong-Won, Kim, Kyung, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Nam, Do-Hyun, Lee, Jeong-Won, Park, Keunchil, Kim, Kyoung-Mee, Lee, Jeeyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268171/ https://www.ncbi.nlm.nih.gov/pubmed/32536979 http://dx.doi.org/10.1177/1758835920926796 |
Ejemplares similares
-
Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
por: Kim, Hyun Jung, et al.
Publicado: (2019) -
Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017) -
Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018) -
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017) -
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)